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Introduction
Worldwide, today’s healthcare environment stresses the pro-
vision of high-quality care while reducing costs. In the United 
States (US), federal payments to healthcare providers have been 
tied to various activities: participation in improvement projects, 
quality metrics, and resource utilization through pay-for-per-
formance programs such as the Merit-Based Incentive Payment 
System (MIPS) developed by the Center for Medicare and Med-
icaid Services (CMS) [1]. This growing trend is taking place in 
other industrialized countries that face the dilemma of rapidly 
rising healthcare costs [2] and is, in part, responsible for recent 
innovations in hospital-based care. In the perioperative setting, 
implementation of standardized multimodal analgesia (MMA) 
represents one such innovation. 
MMA can be defined as the use of more than one pharmaco-
logical class of analgesic medication targeting different receptors 
along the pain pathway with the goal of improving analgesia 
while reducing individual class-related side effects [3]. The con-
cept of MMA is not new, but the current need for MMA and 
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minimizing opioid use is clearly evident in light of the opioid 
epidemic as well as ubiquitous drug shortages facing the US and 
other countries. MMA is recommended for postoperative pain 
in many clinical situations and is the key focus of a joint clinical 
practice guideline from the American Pain Society, American 
Society of Regional Anesthesia and Pain Medicine (ASRA), and 
the American Society of Anesthesiologists [4]. Designing an 
ideal perioperative pain management strategy should always 
start with MMA, and this article will review the evidence for this 
recommendation including support for individual components 
and the role of MMA in addressing the opioid epidemic. In this 
review, we will examine MMA both in the broader context of 
perioperative care as well as in its specific application in patients 
undergoing total knee arthroplasty (TKA), a procedure that has 
been the focus of substantial attention as some projections pre-
dict 3.48 million primary and 268,200 revision TKA procedures 
will be performed annually by 2030 [5].  
Elements of Multimodal Analgesia
Perioperative pain consists of multiple pain subtypes and as 
such cannot be effectively treated with a single medication. Sur-
gical pain may be nociceptive, neuropathic, mixed, psychogenic, 
or idiopathic [6], depending on the surgery. Kehlet and Dahl [7] 
recognized the value of balanced analgesia or MMA over two 
decades ago when they published one of the earliest papers ad-
vocating the use of multiple agents rather than a single agent in 
treating postoperative pain. A good MMA protocol is a checklist 
rather than a recipe; it will standardize the categories of anal-
gesics while still allowing for some flexibility in the individual 
components based on patient comorbidities, allergies, medica-
tions, and previous surgical experiences. For example, although 
gabapentinoids have been shown to be opioid sparing when part 
of a multimodal protocol [8], they can cause sedation [9], partic-
ularly in the elderly, and a protocol that includes gabapentinoids 
may have limitations on the maximum patient age for the drugs 
or a dose adjustment. A patient with a sulfa allergy may present 
for elective TKA which precludes celecoxib; rather than elimi-
nating all cyclooxygenase (COX) inhibitors, an alternative, such 
as ibuprofen or naproxen, can be given. Anticipating common 
allergies and side effects in certain populations will help main-
tain adherence to multimodal protocols.
Non-opioid systemic analgesics
Non-opioid analgesics are the cornerstone on which to build 
a successful perioperative MMA regimen (Table 1). In addition 
to the absence of opioid side effects, many of these agents are 
highly effective in reducing postoperative pain and allowing 
for faster mobilization and meeting milestones. The first med-
ication, acetaminophen, is one that has been in clinical use 
for decades with a proven track record of safety when used in 
appropriate doses. Many current multimodal protocols include 
acetaminophen [8,10,11], and its opioid-sparing effects and ab-
sence of contraindications outside of severe liver disease make 
it appealing. Though not adequate alone for painful procedures 
such as TKA, it is definitely a useful and inexpensive component 
of the protocol. Current evidence does not support the use of 
intravenous (IV) acetaminophen over oral (PO) acetaminophen 
universally [12], but for specific indications (e.g., long proce-
dures or patients not able to take PO medications) the IV for-
mulation is a good option.
Non-steroidal anti-inflammatory drugs (NSAIDs) represent 
another class of medication that is highly effective for periop-
erative pain management and should be considered for MMA 
protocols. NSAIDs exert their effects through inhibition of 
COX and prostaglandin synthesis [8]. Despite concerns about 
the increased risk of postoperative bleeding with NSAIDs, a 
meta-analysis has revealed that ketorolac does not increase the 
risk of perioperative bleeding [13]. In a systematic review, the 
combination of ibuprofen 400 mg and paracetamol (i.e., acet-
aminophen) 1000 mg had a number needed to treat of only 1.5 
to achieve 50% postoperative pain relief or greater [14]. Caution 
should be exercised in patients with renal disease and gastro-
intestinal ulcers [8]. In addition, all NSAIDs increase the risk 
of cardiovascular events, including myocardial infarction [15]. 
In patients in whom gastrointestinal ulcers are of particular 
concern, a COX-2 selective inhibitor may be substituted for a 
Table 1. Commonly Used Perioperative Systemic Non-opioid Multimodal Analgesics in Adults
Drug Route (s) Preoperative dose Intraoperative dose Postoperative dose
Acetaminophen IV/PO 1000 mg (> 50 kg) 1000 mg 1000 mg q6h
Celecoxib PO 400 mg N/A 200 mg q12h
Gabapentin PO 300–1200 mg N/A 300–800 mg q8h
Ketamine IV N/A 0.25–0.5 mg/kg bolus 0.25 mg/kg/h infusion
Ibuprofen IV/PO 600–800 mg N/A 600 g q6h
Pregabalin PO 75–150 mg N/A 75 mg q12h
IV: intravenous, N/A: not applicable, PO: by mouth.
347Online access in http://ekja.org
KOREAN J ANESTHESIOL Schwenk and Mariano
non-selective agent to decrease this risk [16]. 
Another class of analgesics commonly used in MMA proto-
cols is the gabapentinoids, which include gabapentin and pre-
gabalin. As anti-convulsants they exert their clinical effects via 
interaction with voltage-gated calcium channels [17]. Meta-anal-
yses have demonstrated that gabapentin [18] and pregabalin [19] 
improve postoperative pain when part of a MMA regimen but 
are associated with sedation. In particular, elderly patients are 
vulnerable to this side effect, and consideration should be given 
to lowering the dose or avoiding them altogether. For patients 
who may have symptoms that suggest neuropathic pain, such 
as pain with a burning quality, these agents may be particularly 
useful.
Other agents to consider in MMA protocols include N-meth-
yl-D-aspartate (NMDA) antagonists, with focus on ketamine 
and magnesium in particular. Ketamine has a clear opioid-spar-
ing effect in the perioperative period [20] and may even reduce 
long-term opioid consumption in opioid-tolerant patients [21] 
as well as persistent postsurgical pain when used intravenously 
[22]. It is increasingly being featured in MMA protocols as an 
opioid alternative [23]. Although reviews have not consistently 
shown an increased incidence of side effects compared to con-
trols [20,24], ketamine has the potential to cause psychomimetic 
effects and this should be factored into treatment decisions. Its 
benefits are maximized during painful surgery, including TKA, 
and opioid-tolerant patients may particularly benefit. ASRA has 
recently published guidelines for the use of ketamine in acute 
pain management [25].
Magnesium has produced mixed results as a postoperative 
analgesic when used alone [26,27] but has demonstrated syn-
ergism when combined with morphine or ketamine [26]. It is 
thought to exert its effects via spinal NMDA receptors and ap-
pears to be more effective when used intrathecally rather than 
intravenously [26]. Nevertheless, it is an inexpensive addition 
to a multimodal regimen that may be considered especially if 
there are contraindications or allergies that limit the use of other 
non-opioid agents.
Local Anesthetics
Regional anesthesia and analgesia techniques
Any discussion of MMA and opioid-sparing techniques must 
include regional anesthesia, which is the use of local anesthetics 
to anesthetize discreet areas of the body. Regional anesthesia 
provides superior pain control compared to traditional opi-
oid-based strategies in many types of surgery, including TKA 
[28], shoulder surgery [29], foot and ankle surgery [30], and 
colorectal surgery [31] and can decrease nausea and vomiting as 
well as the time spent in the post-anesthesia care unit [32]. Re-
gional anesthesia includes both neuraxial (spinal and epidural) 
anesthesia and peripheral nerve blocks. For surgical procedures 
amenable to regional anesthesia, such as upper or lower ex-
tremity surgery, incorporating blocks can be a highly effective 
method of minimizing opioids and providing excellent anal-
gesia. Nerve blocks do carry a risk of complications, including 
nerve injury, bleeding, infection, and rebound pain, and these 
should be weighed against the potential benefits. Nerve block 
duration can be prolonged by either placing a continuous nerve 
block (i.e., perineural catheter) [33] or adding adjuvants to the 
perineural mixture. Although not approved for this indication 
in the US, perineural dexamethasone has been shown to extend 
the duration of brachial plexus block by 6–8 h [34] and sciatic 
nerve block by 13 h [35]. Dexmedetomidine can prolong blocks 
as well, with a mechanism likely similar to clonidine, although 
bradycardia may be an issue [36].
Continuous peripheral nerve blocks offer an alternative to 
adjuvants to extend the effects of nerve blocks if trained staff are 
available and a system is in place to care for the patients who re-
ceive them. For TKA, one study concluded that single-injection 
adductor canal block (ACB) is non-inferior to continuous ACB 
regarding pain and opioid consumption in 48 h [37]. This is en-
couraging for those practices that do not have resources in place 
for continuous nerve block follow-up. Another recent study has 
concluded that a continuous femoral nerve block may not de-
crease pain or opioid consumption compared to single-injection 
femoral nerve block after TKA [38]. That being said, continu-
ous peripheral nerve blocks tend to result in less nausea, fewer 
opioids, and greater satisfaction with pain management overall 
than alternative techniques [39]; they also allow for individual 
titration of effect, prolongation of analgesia when needed, and 
patient-controlled analgesia. Although the addition of perineu-
ral adjuvants like dexamethasone may raise concern for neuro-
toxicity based on animal studies [40], this has not been consis-
tently borne out in human studies [41]. Therefore, the choice of 
adjuvant or catheter-based technique should be specific to the 
practice and may be made based on the training of personnel, 
experience, and logistics.
Local infiltration analgesia
Some surgeons may prefer the injection of local anesthetics 
directly into the vicinity of the wound for certain surgeries rath-
er than regional anesthesia for various reasons, including con-
cerns over motor weakness, the need to check nerve function 
postoperatively, or system-related issues. Wound infiltration 
techniques have been shown to provide some analgesia for lapa-
roscopic cholecystectomy [42] and cesarean section [43], but the 
magnitude of analgesia and opioid sparing appears to be small 
and short-lived. Nevertheless, if peripheral or neuraxial blocks 
348 Online access in http://ekja.org
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are not an option, wound infiltration may provide some bene-
fit especially when included as part of an overall perioperative 
MMA strategy.
For TKA, local anesthetics and other medications may be 
injected directly around the joint to improve pain control with 
or without the addition of peripheral nerve blocks although the 
combination of the two may be advantageous [44,45]. Periartic-
ular infiltration analgesia may be comparable to femoral nerve 
block for the first 48 h after TKA, although femoral nerve block 
reduces opioid consumption to a greater degree [46]. Periarticu-
lar multimodal ‘cocktails’ typically consist of a dilute local anes-
thetic in addition to medications such as NSAIDs, epinephrine, 
and opioids [47,48]. While local anesthetic infiltration is com-
monly performed by surgeons [49], a newer ultrasound-guided 
technique known as the IPACK (infiltration between the popli-
teal artery and the capsule of the knee) facilitates performance 
by the anesthesiologist [50].
Intravenous local anesthetics
Intravenous local anesthetics, specifically lidocaine, may 
have a role in MMA protocols as well as Enhanced Recovery 
after Surgery (ERAS) protocols. Limited evidence suggests that 
lidocaine infusions reduce pain and opioid consumption as well 
as expedite return of bowel function after abdominal surgery 
[51] and analgesia during the first 48 h after spine surgery [52]. 
A meta-analysis in breast surgery found that acute postoperative 
pain was not improved with lidocaine infusions, but the risk of 
developing persistent postsurgical pain was reduced [53]. How-
ever, inclusion of a small number of studies limits this review. 
Lidocaine attenuates a number of pro-inflammatory molecules 
[54], and this is one proposed mechanism for its periopera-
tive analgesic effects. As a generic drug, it is not expensive and 
should be considered as a component of ERAS protocols for ab-
dominal surgery if epidural analgesia is contraindicated or not 
desired [55].
Opioid analgesics
Opioids have long been the standard perioperative analgesics 
of choice, a trend largely based on their simplicity, predictability, 
and familiarity. However, in light of the current opioid epidemic 
and greater awareness of opioid-related adverse events, atten-
tion has shifted from opioids to non-opioid analgesics as the 
foundation for perioperative pain management. The concept of 
reserving opioids for moderate or severe pain after alternatives 
have failed is not new and in fact was a cornerstone of the World 
Health Organization’s analgesic ladder that was first proposed in 
1986 then recently updated with renewed emphasis on non-opi-
oids as first-line for non-cancer pain [56]. As recent data reveal, 
MMA protocols for total joint arthroplasty (TJA) continue to 
include opioids as a component [57], and they are unlikely to 
be eliminated completely from the perioperative experience. 
However, the ever-expanding array of non-opioid agents has 
deepened the clinical armamentarium and given perioperative 
physicians the ability to minimize opioid exposure. Commonly 
used oral perioperative opioids include hydrocodone, oxyco-
done, and tramadol. Hydrocodone exists in several combination 
formulations and oxycodone is produced both in combination 
with acetaminophen and alone. Although commonly viewed 
as less likely to be abused because of its lower µ-opioid receptor 
affinity, tramadol has been highlighted in a 2017 report by the 
Centers for Disease Control and Prevention (CDC) for its as-
sociation with long-term opioid use as well as a recent spike in 
emergency room visits [58]. Therefore, substituting tramadol 
for other opioids after surgery is likely not a significant improve-
ment in safety or addiction potential.
Multimodal Analgesia, the Opioid Epidemic, 
and the Crisis of Drug Shortages
Evidence is accumulating that the risk of long-term opioid 
use after surgery increases with the length of initial prescription. 
Sun et al. [59] have reported that the risk of chronic opioid use 
in opioid-naïve patients after surgery is increased compared to 
that of non-surgical patients. In 8 of the 12 surgery types stud-
ied, including TKA, patients have an increased risk of filling 
either 10 or more prescriptions or more than 120 days’ worth, 
excluding the first 90 days. Brummett et al. [60] have also stud-
ied opioid-naïve patients who underwent a variety of surgeries, 
excluding orthopedic surgery, and similarly report an elevated 
risk among all surgical patients for long-term opioid use (defined 
as a prescription filled between 90 and 180 days). Interestingly, 
their reported rates of chronic use do not vary between minor 
and major surgical procedures. At the same time, the CDC has 
warned that the risk of long-term opioid use spikes at both 5 
and 30 days in the initial prescription window [58]. Given the 
risk of long-term use that surgery itself introduces combined 
with the risk associated with prescriptions beyond a few days, 
efforts to reduce unnecessary opioid prescribing are warranted 
and already underway. Certainly, much of the focus is on opioid 
prescribing patterns, which we will not discuss here, but the im-
plementation of MMA into routine perioperative care whenever 
possible is a step in the right direction. 
Hebl et al. [11] have demonstrated that a TKA MMA proto-
col featuring a peripheral nerve block can produce meaningful 
benefits including decreases in length of stay and decreased 
opioid consumption. A large database study in patients who 
underwent TJA reports that, with each non-opioid agent added 
to a perioperative multimodal regimen, patients show a step-
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wise decrease in opioid consumption, opioid prescriptions, and 
length of stay [57]. Similar patterns have been noted outside of 
TJA as well. In a study of minor aesthetic plastic surgery proce-
dures, switching from an opioid-based strategy to a non-opioid 
one does not compromise analgesia but does reduce nausea and 
vomiting and recovery time [61]. 
The concept of opioid-free surgery has been introduced and 
trialed at select institutions, although overall adoption has been 
slow and inconsistent [62]. Some proposed indications for opi-
oid-free surgery include obesity, obstructive sleep apnea, chron-
ic obstructive pulmonary disease, complex regional pain syn-
drome, cancer, and opioid tolerance [63]. Although conceptually 
it is logical that opioid-free surgery would reduce opioid-related 
complications and improve the perioperative patient experience, 
few outcome data have been published. When incorporated into 
an ERAS protocol, opioid-free surgery does not significantly 
reduce opioid prescribing patterns at discharge, even when pain 
scores and opioid use are low prior to discharge [64]. Clearly, 
there is still work to be done in determining the effect of opi-
oid-free surgery on important outcomes and then accomplish-
ing that goal in clinical practice. Any efforts to this end will rely 
heavily on MMA.
An additional challenge in managing perioperative pain to-
day is that of ongoing drug shortages. Virtually every hospital 
and practice in the US has experienced this to some degree in 
recent years, and it can significantly alter a patient’s treatment. 
The causes of drug shortages are multifactorial and include 
quality and regulatory issues, company decisions to change 
strategy or discontinue manufacturing of a drug, or a shortage 
of raw materials [65]. Because three pharmaceutical companies 
manufacture 70% of the injectable medications used in the US 
and some perioperative medications are almost exclusively made 
by one company [65], shortages can have major, far-reaching 
effects on MMA strategies. Creating protocols that have some 
flexibility, such as substituting gabapentin for pregabalin or us-
ing alternative NSAIDs if one is not available, will prevent entire 
classes of drugs from being omitted in the perioperative period. 
This may not always be possible for agents with unique mech-
anisms of action, but for others it gives prescribing clinicians 
some options. 
Anesthesiologists must also be creative at times when pre-
ferred drugs are not available and may need to turn to older 
drugs that are no longer commonly used. In one example from 
Canada, the local anesthetic chloroprocaine, a short-acting 
agent suitable for shorter procedures that was developed decades 
ago, was not readily available because of a lack of regulatory 
approval; anesthesiologists turned to prilocaine, an alternative 
intermediate-acting local anesthetic [66]. Although a lack of 
clinical studies comparing prilocaine to the more commonly 
used ropivacaine initially impeded its use, eventually studies 
were performed that justified the production and use of the 
older drug prilocaine [66]. This example may be particularly 
relevant for other generic drugs that are produced by one or a 
limited number of companies. Reliance on a single agent in any 
drug class used in perioperative pain management is no longer 
acceptable now that drug shortages are so common, and addi-
tional clinical studies of alternative drugs are needed to support 
their use. All anesthesiologists must develop a strong working 
relationship with their pharmacy colleagues in every practice lo-
cation to develop a solid plan in terms of medication supply and 
alternatives in this era of frequent drug shortages so patients can 
continue to receive consistently high quality pain management 
in the perioperative period. Longer term solutions will require 
the involvement of professional societies and engagement of leg-
islators.
Conclusions
In summary, evidence today supports the routine use of 
multimodal analgesia in the perioperative period to eliminate 
the over-reliance on opioids for pain control and to reduce 
opioid-related adverse events. A multimodal analgesic protocol 
should be surgery-specific, functioning more like a checklist 
than a recipe, with options to tailor to the individual patient. 
Elements of this protocol may include opioids, non-opioid sys-
temic analgesics like acetaminophen, NSAIDs, gabapentinoids, 
ketamine, and local anesthetics administered by infiltration, 
regional block, or the intravenous route. While implementation 
of multimodal analgesic protocols perioperatively is recom-
mended as an intervention to decrease the prevalence of long-
term opioid use following surgery, the concurrent crisis of drug 
shortages presents an additional challenge. Anesthesiologists 
and acute pain medicine specialists will need to advocate locally 
and nationally to ensure a steady supply of analgesic medica-
tions and in-class alternatives for their patients’ perioperative 
pain management.
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